Overall, our data point out Jagged1 overexpression as a new potential predictive biomarker that is useful in predicting cancer progression and drug resistance to current therapies for early and advanced CRC favoring tumor relapse. This evidence concerns the gene JAG1 and colorectal carcinoma.